Breast Cancer Clinical Trial
Official title:
Diagnostic Accuracy of Between Side Differences of Ultrasonographic Dermal Thickness Measurements in Breast Cancer Related Arm Lymphedema
Ultrasound is an easily feasible noninvasive technique which is widely used in rehabilitation settings. Measurement of dermal thickness via ultrasound can be less time consuming than volume measurements with water displacement and circumference measurements. Measurement of subcutaneous tissue thickness were used for both assessment and treatment outcome. Recently reliability of ultrasound examination of thickness of the skin and subcutaneous tissue were studied by Han et al. However, diagnostic accuracy of this method has not been studied before. Early identification of breast cancer related lymphedema to start treatment earlier is critical. Consequently, reliability and diagnostic accuracy of the assessment techniques of lymphedema is crucial to evaluate both severity at the time of diagnosis, and later effectiveness of treatment. The aim of this study was to establish diagnostic accuracy of between side differences of ultrasonographic dermal thickness measurements in breast cancer related arm lymphedema.
Breast cancer related arm lymphedema is a potential sequalae from the treatment of breast
cancer which is characterized by the accumulation of protein-rich lymphatic fluid in the
extracellular spaces. It may occur in almost 40% of the patients who have undergone breast
cancer surgery or radiation therapy. Breast cancer related lymphedema may appear in the upper
extremity, as well as in the ipsilateral upper quadrant and remaining breast tissue.
Clinically, the diagnosis of lymphedema is based mainly on patient history and self-report of
symptoms, visual inspection and skin palpation, and the determination of volume differences
between both limbs. The most widely accepted measure of lymphedema is limb volume compared
with that of the unaffected limb or compared with that of the same limb. Sequential
circumference measurements along designated measure points are widely used in clinical
practice. Limb volumes can be calculated or estimated based on a truncated cone formula.
Volumetry by means of water displacement is considered the golden standard. The most common
criterion for lymphedema diagnosis is a volume difference of 200 mL. Circumference
measurements and the estimated volume were found to be reliable and highly correlated with
each other. However, these volume measurements are not only influenced by fluid changes but
also by compositional changes of muscle mass, bone, or fat. Also, water displacement is too
cumbersome and messy to be used in routine clinical practice.
Ultrasound is an easily feasible noninvasive technique which is widely used in rehabilitation
settings. Measurement of dermal thickness via ultrasound can be less time consuming than
volume measurements with water displacement and circumference measurements. Measurement of
subcutaneous tissue thickness were used for both assessment and treatment outcome. Recently
reliability of ultrasound examination of thickness of the skin and subcutaneous tissue were
studied by Han et al. However, diagnostic accuracy of this method has not been studied
before. Early identification of breast cancer related lymphedema to start treatment earlier
is critical. Consequently, reliability and diagnostic accuracy of the assessment techniques
of lymphedema is crucial to evaluate both severity at the time of diagnosis, and later
effectiveness of treatment. The aim of this study was to establish diagnostic accuracy of
between side differences of ultrasonographic dermal thickness measurements in breast cancer
related arm lymphedema. Patients with breast cancer related lymphedema will be included.
Lymphedema of the limbs will be assessed using the circumferential method. The
circumferential upper limb measurementswill be carried out with the arm abducted at 30°,
starting at the level of the carpometacarpal joint, every 5 cm proximal to this point along
both limbs. Then, a computer program (limb volumes professional version 5.0) will be used to
convert these values into limb volumes in milliliters. Differences in volume of affected and
unaffected sides was defined as edema (volume difference). The criterion for lymphedema
diagnosis is volume difference of 200 mL. Ultrasonographic dermal thickness measurements will
be performed from medial forearm. Differences of the affected and unaffected sides will be
calculated. The circumference measurement method and the thickness of the skin of the
edematous limb by using the ultrasound and the truncated cone method by using circumference
measurements will be compared to evaluate the diagnostic accuracy of between side differences
of ultrasonographic dermal thickness measurements in breast cancer related arm lymphedema.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |